Chemotherapy Improves Clinical Outcomes in Certain NSCLC Patients
Numerous studies have demonstrated that the addition of chemotherapy to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors has the potential to expand progression-free survival in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, the effectiveness of these agents in patients with brain metastases remains uncertain. Learn more about a recent study that helped address this uncertainty.

Cost Effectiveness of Risk-Based Lung Cancer Screening
According to a recent study that was published in the Annals of Internal Medicine, a risk-based lung cancer screening program was more cost-effective than the updated United States Preventive Services Task Force (USPSTF) recommendations. Implementing models of individualized lung cancer risk should be considered for future USPSTF recommendations. Learn more about the results of this study.

Targeted Therapies Underused in Medicaid Programs
Findings from a recent study published in the Journal of the American Medical Association reveal that targeted therapies for treating patients with epidermal growth factor receptor mutations and anaplastic large-cell lymphoma kinase altered, metastatic non-small cell lung cancer are often underutilized in many state Medicaid programs. This restricts access to efficacious treatments. Learn more about the results of this study.